LNC
IONS icon

Lincoln National Corp’s Ionis Pharmaceuticals IONS Stock Holding History

Lincoln National Corp’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,034
Closed -$466K – 1054
2023
Q1 		$466K Sell
13,034
-65
-0.5% -$2.44K 0.01% 614
2022
Q4 		$495K Buy
13,099
+269
+2% +$11.3K 0.01% 541
2022
Q3 		$567K Sell
12,830
-431
-3% -$18.2K 0.01% 460
2022
Q2 		$491K Hold
13,261
– – 0.01% 485
2022
Q1 		$491K Sell
13,261
-809
-6% -$26.5K 0.01% 530
2021
Q4 		$428K Sell
14,070
-200
-1% -$6.29K 0.01% 582
2021
Q3 		$479K Sell
14,270
-800
-5% -$30.1K 0.01% 520
2021
Q2 		$601K Sell
15,070
-395
-3% -$15.5K 0.01% 437
2021
Q1 		$695K Sell
15,465
-1,640
-10% -$91.5K 0.02% 379
2020
Q4 		$967K Hold
17,105
– – 0.03% 288
2020
Q3 		$812K Sell
17,105
-212
-1% -$11.8K 0.02% 293
2020
Q2 		$1.02M Sell
17,317
-255
-1% -$14.2K 0.03% 243
2020
Q1 		$831K Sell
17,572
-902
-5% -$50.3K 0.03% 241
2019
Q4 		$1.12M Buy
18,474
+500
+3% +$29.8K 0.04% 241
2019
Q3 		$1.08M Buy
17,974
+543
+3% +$35.4K 0.04% 215
2019
Q2 		$1.12M Sell
17,431
-1,787
-9% -$126K 0.04% 191
2019
Q1 		$1.56M Buy
19,218
+2,137
+13% +$138K 0.06% 141
2018
Q4 		$923K Sell
17,081
-2,060
-11% -$105K 0.04% 191
2018
Q3 		$987K Buy
19,141
+2,959
+18% +$139K 0.03% 179
2018
Q2 		$674K Buy
16,182
+3,610
+29% +$160K 0.02% 220
2018
Q1 		$554K Sell
12,572
-12,642
-50% -$642K 0.02% 253
2017
Q4 		$1.27M Buy
25,214
+20,162
+399% +$1.11M 0.04% 206
2017
Q3 		$256K Buy
+5,052
New +$265K 0.01% 347

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Lincoln National Corp's IONS Position: Q2 2023 in Review

Lincoln National Corp sold out of Ionis Pharmaceuticals (IONS) in Q2 2023, closing a stake of 13,034 shares — an estimated $466K sold.

Lincoln National Corp first reported a position in IONS in Q3 2017 and held it in 23 quarters. The position peaked at $1.56M in Q1 2019. 304 funds tracked by Wall St. Rank hold IONS as of Q2 2023.

  • Lincoln National Corp reported no remaining Ionis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Lincoln National Corp sold 13,034 Ionis Pharmaceuticals shares in Q2 2023, an estimated $466K.
  • Lincoln National Corp first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 23 quarters.
  • Lincoln National Corp's Ionis Pharmaceuticals position peaked at $1.56M in Q1 2019.
  • 304 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2023.

Based on Lincoln National Corp's 13F filing for Q2 2023, filed 7 Aug 2023.